Test Price
1,600 AED✅ Home Collection Available
IDH1 & IDH2 Mutation Analysis in UAE | 1,600 AED | DHA Licensed Lab
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 Accredited Sanger Sequencing with dual-strand bidirectional verification for definitive IDH1 and IDH2 variant calling.
Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE tumor tissue blocks and slides, fully coordinated by our DHA-licensed clinical team.
Clinical Guidance: Telephonic post-test clinical guidance and result interpretation provided by a Consultant Medical Geneticist specialized in molecular oncology.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The IDH1 and IDH2 Mutation Analysis is a high-precision molecular diagnostic test that detects somatic point mutations in the isocitrate dehydrogenase 1 and 2 genes using gold-standard Sanger Sequencing technology. This analysis is essential for the diagnosis, prognosis, and targeted therapy stratification of gliomas, acute myeloid leukemias, chondrosarcomas, and select cholangiocarcinomas. Our focused Sanger approach provides faster turnaround and reduced cost compared to broad NGS panels without compromising base-level accuracy for clinically actionable hotspot codons (IDH1 R132, IDH2 R140/R172).
| Feature | Our Test — Sanger Sequencing | Closest Alternative — NGS Panel |
|---|---|---|
| Diagnostic Precision | 99.9% per-base accuracy with bidirectional sequencing confirmation | 98–99% depending on coverage depth; variant calls often require orthogonal confirmation |
| Mutation Coverage | Full coding region of IDH1 (exon 4, codon R132) and IDH2 (exon 4, codons R140, R172) | Broader multi-gene panel; may miss low-frequency IDH2 variants if depth insufficient |
| Turnaround Time | 7–8 Days | 14–21 Days |
| Cost in UAE | 1,600 AED | 2,500–4,000 AED |
| Clinical Applicability | Focused, clinically actionable results aligned with WHO CNS5 and ELN 2024 guidelines | Incidental findings may require additional genetic counseling resources |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh
DHA Registration ID: 9294403 | Consultant Medical Genetics
As a Consultant Medical Geneticist, I consider IDH1 and IDH2 mutations to be defining molecular milestones in neuro-oncology and hematopathology. The presence of an IDH mutation fundamentally alters the diagnostic classification, carries significant prognostic weight, and directly unlocks targeted therapies such as vorasidenib for low-grade gliomas and ivosidenib or enasidenib for AML. However, it is critical that the mutational status is interpreted alongside histopathological review, radiological findings, and the complete clinical context. No single biomarker should drive clinical decisions in isolation.
⚠ Medication Safety Advisory
IMPORTANT: Do not start, stop, or modify any IDH inhibitor therapy without direct supervision from your treating oncologist or hematologist.
IDH inhibitor therapies (e.g., ivosidenib, enasidenib, vorasidenib) have specific indications, dosing protocols, and potential adverse effects such as differentiation syndrome or QT prolongation that require expert management. Abrupt cessation may lead to disease progression.
⚠ Patient Safety — Exclusion Criteria & Emergency Red Flags
Pre-Procedure Exclusion Criteria for Tumor Tissue Sampling:
- Uncorrected coagulopathy (INR > 1.5, Platelets < 50,000/µL)
- Active systemic infection or sepsis
- Inaccessible tumor site precluding safe biopsy
- Patient on dual antiplatelet therapy without a bridging plan
- Pregnancy with contraindication to anesthesia
Emergency Red Flags — Seek Immediate Medical Attention:
- Uncontrolled bleeding at biopsy site persisting beyond 24 hours
- Sudden neurological deterioration (severe headache, vision loss, seizure)
- Signs of infection: fever > 38.5°C, purulent discharge, spreading erythema
- Acute dyspnea or chest pain (potential thromboembolic event)
- Severe abdominal pain or compartment syndrome post-procedure
Patient FAQ & Clinical Guidance
1. What is the IDH1 & IDH2 mutation analysis test used for?
This test identifies specific somatic mutations in the IDH1 and IDH2 genes from tumor tissue. It is clinically indicated for guiding accurate cancer diagnosis, predicting patient prognosis, and determining eligibility for targeted IDH-inhibitor therapies. It is most commonly used for gliomas (brain tumors), acute myeloid leukemia (AML), chondrosarcomas, and intrahepatic cholangiocarcinomas, where IDH mutational status directly influences WHO grading classification and therapeutic decision-making.
2. How is the test performed and what sample is required?
This analysis requires a formalin-fixed paraffin-embedded (FFPE) tumor tissue sample, typically obtained through a clinically indicated biopsy or surgical resection performed by your treating physician. Our laboratory coordinates Secure Medical Courier Solid Tissue Specimen Retrieval to transport the archival FFPE blocks or slides directly to our ISO 15189-accredited facility, where DNA extraction and Sanger sequencing analysis is performed under strict quality-controlled protocols.
3. What is the turnaround time, cost, and insurance coverage in the UAE?
Results are delivered within 7 to 8 working days at a total cost of 1,600 AED. We accept all major UAE medical insurance providers and offer a streamlined pre-authorization process. For uninsured patients, transparent self-pay options with itemized invoicing are provided to ensure complete financial clarity before testing commences. Direct insurance billing verification is available exclusively through our dedicated WhatsApp support line at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
• Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — All patient genomic data encrypted and stored within UAE sovereign data infrastructure.
• Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — Governing secure electronic health data exchange and telemedicine integration.
• Federal Decree-Law No. 4 of 2016 on Medical Liability — Establishing patient consent frameworks and clinical accountability standards for diagnostic procedures.
• ISO 9001:2015 Certified — Cert: INT/EGQ/2509DA/3139
• DHA Facility License: 1143
• Corporate Lab Branding: DNA Labs UAE
Schedule Your IDH1 & IDH2 Mutation Analysis Today
Secure Courier Retrieval: Coordinated by Clinical Team | Results: 7–8 Days | 1,600 AED | DHA-Approved Laboratory
WhatsApp: +971 54 548 8731
Prescription from a treating physician required. Not applicable for over-the-counter or direct patient-initiated testing. Clinical coordination and pre-test counseling are mandatory components of this service.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians